  |
||||
|
Orchid Chemicals & Pharmaceuticals Ltd. |
||||
|
Unaudited Financial Results for the quarter ended June 30, 2010 |
(Rs. Lakhs) |
|||
| S.No |
Particulars |
Three Months ended 30-Jun-10 (Unaudited) |
Three Months ended
30-Jun-09 (Unaudited) |
Year ended 31-Mar-10 (Audited) |
|
1 |
Net Sales | 30,350.00 |
30,581.89 |
120,518.59 |
|
2 |
Other Operating Income | 2,742.83 |
301.17 |
4,585.61 |
3 |
Total Operating Income (1+2) |
33,092.83 |
30,883.06 |
125,104.20 |
|
4 |
Expenditure | |||
|
a) Decrease/(Increase) in Stock in trade |
(2,192.44) |
(2,677.99) |
26,945.14 |
|
b) Material Cost |
16,224.53 |
12,708.86 |
47,207.23 |
|
c) Purchase of Trades Goods |
961.36 |
871.06 |
3,373.83 |
|
d) Employees Cost |
3,032.85 |
2,896.22 |
15,929.17 |
|
e) Depreciation / Amortisation |
3,226.03 |
3,732.56 |
15,110.40 |
|
f) Other Expenditure |
6,688.73 |
10,593.18 |
48,763.98 |
|
g) Total |
27,941.06 |
28,123.89 |
157,329.75 |
|
|
5 |
Profit from Operations before other Income, Interest & Exceptional Item
(3 - 4) |
5,151.77 |
2,759.17 |
(32,225.55) |
6 |
Other Income |
- |
0.46 |
7.41 |
7 |
Profit before Interest & Exceptional Item (5+6) |
5,151.77 |
2,759.63 |
(32,218.14) |
|
8 |
Interest & Finance Charges | 2,271.27 |
5,166.30 |
24,123.31 |
9 |
Profit/(loss) after interest but before Exceptional Item (7-8) |
2,880.50 |
(2,406.67) |
(56,341.45) |
|
10 |
Exceptional Item - Gain/(Loss) |
(469.86) |
(363.54) |
816.55 |
|
11 |
Profit/ (Loss) before Tax (9+10) |
2,410.64 |
(2,770.21) |
(55,524.90) |
|
12 |
Tax expenses |
|||
| - Current Tax & Deferred Tax | 249.16 |
205.84 |
- |
|
|
13 |
Net Profit/ (Loss) after Tax (11-12) | 2,161.48 |
(2,976.05) |
(55,524.90) |
14 |
Extraordinary Item (net of tax of Rs.12871.42 lakhs) | - |
- |
88,658.86 |
15 |
Net Profit/(Loss) for the period/year | 2,161.48 |
(2,976.05) |
33,133.96 |
|
16 |
Paid- up Equity Share Capital (Face value of Rs. 10 each) | 7,044.21 |
7,044.21 |
7,044.21 |
|
17 |
Reserves excluding Revaluation Reserves | 90,919.30 |
||
|
18 |
Earnings per Share (EPS) before extraordinary item | |||
|
- Basic Rs. |
3.07* |
(4.22)* |
(78.82) |
|
- Diluted Rs. |
2.44* |
(4.22)* |
(78.82) |
|
19 |
Earnings per Share (EPS) after extraordinary item | |||
- Basic Rs. |
3.07* |
(4.22)* |
47.04 |
|
- Diluted Rs. |
2.44* |
(4.22)* |
37.31 |
|
20 |
Aggregate of Public Shareholding |
|||
| - Number of equity shares | 52128460 |
55525904 |
52128460 |
|
| - Percentage of Shareholding | 74.00 |
78.82 |
74.00 |
|
21 |
Promoters and Promoter group shareholding |
|||
a. Pledged / Encumbered |
||||
- Number of shares |
14824327 |
4158000 |
15123760 |
|
- Percentage of shares (as a % of the total shareholding of promoter and promoter group) |
80.95 |
27.88 |
82.58 |
|
- Percentage of shares (as a % of the total share capital of company) |
21.04 |
5.90 |
21.47 |
|
b. Non - Encumbered |
||||
- Numbers of shares |
3489289 |
10758172 |
3189856 |
|
- Percentage of shares (as a % of the total shareholding of promoter and promoter group) |
19.05 |
72.12 |
17.42 |
|
- Percentage of shares (as a % of the total share capital of company) |
4.96 |
15.28 |
4.53 |
|
* EPS for the period (not annualised) |
||||||
1 |
The above unaudited financial results were approved by the Board of Directors at its meeting held on Wednesday, July 21, 2010 and have been subjected to limited review by the Statutory Auditors. | |||||
2 |
The Company is operating in single segment (i.e) "Pharmaceuticals". | |||||
Consolidated Results of the company |
Three months ended 30-Jun-10 |
Three months ended 30-Jun-09 | Audited year ended 31-Mar-10 | |||
| Total Operating Income | 36,456.80 |
33,278.63 |
134,345.33 |
|||
| EBIDTA (After Exceptional Item) | 8,243.11 |
6,496.59 |
86,700.45 |
|||
| Profit After Tax | 2,353.25 |
(2,728.97) |
33,925.41 |
|||
3 |
The Company has acquired US based marketing Company Karalex Pharma, LLC., on July 02, 2010. | |||||
4 |
The Company has exercised the option provided under the Companies (Accounting Standards) Amendment Rules, 2006 dated 31st March, 2009 in respect of AS 11. The amount remaining to be amortized in the financial statements as on June 30, 2010 on account of exercising the above option is Rs. 1418.44 lakhs (Corresponding Quarter of previous year Rs.2700.33 lakhs). | |||||
5 |
Exceptional items represents exchange gain/(loss) on FCCBs. | |||||
6 |
The Company received 9 complaints during the quarter ended June 30, 2010 from the shareholders and no complaints were pending at the close of the quarter. | |||||
7 |
The Current quarter figures do not reflect the sales relating to generic injectable formulation business trasnferred to Hospira Healthcare India Pvt. Ltd., on March 30, 2010. | |||||
8 |
Previous year figures have been regrouped wherever necessary. | |||||
|
||||||